BR0015580A - Composições analgésicas contendo buprenorfina - Google Patents
Composições analgésicas contendo buprenorfinaInfo
- Publication number
- BR0015580A BR0015580A BR0015580-2A BR0015580A BR0015580A BR 0015580 A BR0015580 A BR 0015580A BR 0015580 A BR0015580 A BR 0015580A BR 0015580 A BR0015580 A BR 0015580A
- Authority
- BR
- Brazil
- Prior art keywords
- buprenorphine
- compositions containing
- nalmefene
- naltrexone
- naloxone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
"COMPOSIçõES ANALGéSICAS CONTENDO BUPRENORFINA ". Composição analgésica na forma de dosagem unitária parenteral, ou em uma forma de dosagem adequada para distribuição via mucosa, compreendendo uma quantidade de buprenorfina que é inferior à dose clínica necessária para alcançar alívio da dor; e uma quantidade de naloxona de modo que a relação em peso de buprenorfina para naloxona seja na faixa de 12,5:1 a 27,5:1, ou uma quantidade de naltrexona ou nalmefeno de modo que a relação em peso de buprenorfina para naltrexona ou nalmefeno seja na faixa de 12,5:1 a 22,5:1, com o que a ação analgésica da buprenorfina é potencializada pela baixa dose de naloxona, naltrexona ou nalmefeno.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9927359.1A GB9927359D0 (en) | 1999-11-19 | 1999-11-19 | Improvements in or relating to organic compositions |
US17620800P | 2000-01-14 | 2000-01-14 | |
PCT/GB2000/004372 WO2001035942A2 (en) | 1999-11-19 | 2000-11-17 | Analgesic compositions containing buprenorphine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0015580A true BR0015580A (pt) | 2002-07-09 |
Family
ID=26316086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0015580-2A BR0015580A (pt) | 1999-11-19 | 2000-11-17 | Composições analgésicas contendo buprenorfina |
Country Status (31)
Country | Link |
---|---|
US (4) | US6995169B2 (pt) |
EP (1) | EP1242087B1 (pt) |
JP (1) | JP4745576B2 (pt) |
KR (1) | KR100726699B1 (pt) |
CN (1) | CN100431543C (pt) |
AR (1) | AR031682A1 (pt) |
AT (1) | ATE262335T1 (pt) |
AU (1) | AU777259B2 (pt) |
BR (1) | BR0015580A (pt) |
CA (1) | CA2392013C (pt) |
CO (1) | CO5261517A1 (pt) |
CZ (1) | CZ303160B6 (pt) |
DE (1) | DE60009346T2 (pt) |
DK (1) | DK1242087T3 (pt) |
ES (1) | ES2214334T3 (pt) |
GB (1) | GB2356348B (pt) |
HK (1) | HK1055389A1 (pt) |
HU (1) | HU229565B1 (pt) |
IL (2) | IL149580A0 (pt) |
MX (1) | MXPA02004978A (pt) |
NO (1) | NO321965B1 (pt) |
NZ (1) | NZ519023A (pt) |
PL (1) | PL199727B1 (pt) |
PT (1) | PT1242087E (pt) |
RO (1) | RO121174B1 (pt) |
RU (1) | RU2255737C2 (pt) |
SI (1) | SI21025B (pt) |
SK (1) | SK286888B6 (pt) |
TR (1) | TR200400653T4 (pt) |
TW (1) | TW550070B (pt) |
WO (1) | WO2001035942A2 (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
US20150031718A1 (en) * | 2001-08-06 | 2015-01-29 | Purdue Pharma L.P. | Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
PL2316456T3 (pl) | 2003-04-29 | 2017-12-29 | Orexigen Therapeutics, Inc. | Kompozycje wpływające na utratę masy zawierające antagonistę opioidów i bupropion |
EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
DK2135603T3 (da) | 2005-11-22 | 2013-03-25 | Orexigen Therapeutics Inc | Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
CA2674915C (en) * | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
WO2008051889A1 (en) | 2006-10-24 | 2008-05-02 | The Johns Hopkins University | Rapid release mini-tablets provide analgesia in laboratory animals |
WO2008060964A2 (en) * | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
US20080199407A1 (en) | 2007-02-15 | 2008-08-21 | Slater Kenneth C | Drug Detoxification Protocol Using Microdosing |
GB2447015A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
GB2447013A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition containing buprenorphone and nalmefene |
GB2447014A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
GB2447016A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Buprenorphine/naloxone compositions |
JP2010537989A (ja) * | 2007-09-03 | 2010-12-09 | ナノセラピューティクス・インコーポレイテッド | 難溶性薬物の組成物及び送達方法 |
US20090082383A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched buprenorphine |
US20110144145A1 (en) * | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
MY166034A (en) | 2010-12-22 | 2018-05-21 | Purdue Pharma Lp | Encased tamper resistant controlled release dosage forms |
CA2822769C (en) | 2010-12-23 | 2016-10-04 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
PL2915525T3 (pl) | 2011-09-19 | 2022-01-17 | Orexo Ab | Tabletki podjęzykowe niepodatne na nadużywanie zawierające buprenorfinę i nalokson |
ES2802048T3 (es) | 2012-06-06 | 2021-01-15 | Nalpropion Pharmaceuticals Llc | Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular |
JP6406713B2 (ja) | 2013-01-30 | 2018-10-17 | ファーモレックス セラピューティクス, インコーポレイテッド | 低用量薬剤によるうつ病および他の疾患の処置 |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
EP3043777B1 (en) * | 2013-09-10 | 2020-04-22 | Fresh Cut Development, LLC | Sublingual buprenorphine spray |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
TW201625252A (zh) | 2014-04-22 | 2016-07-16 | 大塚製藥股份有限公司 | 藥物 |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
EP4100012A4 (en) * | 2020-02-05 | 2024-02-07 | Summit Biosciences Inc | MEDICINAL PRODUCTS INTENDED TO BE ADMINISTERED BY INTRANASAL ROUTE AND ASSOCIATED USES |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
GB8430109D0 (en) | 1984-11-29 | 1985-01-09 | Gkn Technology Ltd | Securing components |
GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
GB2213058B (en) * | 1987-12-03 | 1991-07-17 | Reckitt & Colmann Prod Ltd | Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts |
US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US20010006967A1 (en) * | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
CA2408098A1 (en) * | 2000-05-05 | 2001-11-15 | Pain Therapeutics, Inc. | Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists |
-
2000
- 2000-11-16 AR ARP000106062A patent/AR031682A1/es unknown
- 2000-11-17 AT AT00977658T patent/ATE262335T1/de active
- 2000-11-17 CO CO00087459A patent/CO5261517A1/es active IP Right Grant
- 2000-11-17 RO ROA200200620A patent/RO121174B1/ro unknown
- 2000-11-17 CZ CZ20022121A patent/CZ303160B6/cs not_active IP Right Cessation
- 2000-11-17 KR KR1020027006375A patent/KR100726699B1/ko not_active IP Right Cessation
- 2000-11-17 SI SI200020061A patent/SI21025B/sl not_active IP Right Cessation
- 2000-11-17 DK DK00977658T patent/DK1242087T3/da active
- 2000-11-17 PT PT00977658T patent/PT1242087E/pt unknown
- 2000-11-17 DE DE60009346T patent/DE60009346T2/de not_active Expired - Lifetime
- 2000-11-17 CN CNB008159181A patent/CN100431543C/zh not_active Expired - Fee Related
- 2000-11-17 MX MXPA02004978A patent/MXPA02004978A/es active IP Right Grant
- 2000-11-17 ES ES00977658T patent/ES2214334T3/es not_active Expired - Lifetime
- 2000-11-17 BR BR0015580-2A patent/BR0015580A/pt not_active Application Discontinuation
- 2000-11-17 EP EP00977658A patent/EP1242087B1/en not_active Expired - Lifetime
- 2000-11-17 PL PL355330A patent/PL199727B1/pl unknown
- 2000-11-17 WO PCT/GB2000/004372 patent/WO2001035942A2/en active IP Right Grant
- 2000-11-17 NZ NZ519023A patent/NZ519023A/en not_active IP Right Cessation
- 2000-11-17 GB GB0028088A patent/GB2356348B/en not_active Expired - Fee Related
- 2000-11-17 HU HU0203588A patent/HU229565B1/hu not_active IP Right Cessation
- 2000-11-17 RU RU2002116361/15A patent/RU2255737C2/ru not_active IP Right Cessation
- 2000-11-17 IL IL14958000A patent/IL149580A0/xx active IP Right Grant
- 2000-11-17 AU AU15297/01A patent/AU777259B2/en not_active Ceased
- 2000-11-17 CA CA002392013A patent/CA2392013C/en not_active Expired - Fee Related
- 2000-11-17 JP JP2001537935A patent/JP4745576B2/ja not_active Expired - Fee Related
- 2000-11-17 SK SK876-2002A patent/SK286888B6/sk not_active IP Right Cessation
- 2000-11-17 TR TR2004/00653T patent/TR200400653T4/xx unknown
-
2001
- 2001-01-29 TW TW090101624A patent/TW550070B/zh not_active IP Right Cessation
-
2002
- 2002-05-09 IL IL149580A patent/IL149580A/en not_active IP Right Cessation
- 2002-05-14 US US10/145,284 patent/US6995169B2/en not_active Expired - Fee Related
- 2002-05-15 NO NO20022330A patent/NO321965B1/no not_active IP Right Cessation
-
2003
- 2003-10-20 HK HK03107582.6A patent/HK1055389A1/xx not_active IP Right Cessation
-
2005
- 2005-10-20 US US11/254,988 patent/US20060058333A1/en not_active Abandoned
- 2005-10-20 US US11/254,525 patent/US20060069113A1/en not_active Abandoned
- 2005-10-20 US US11/254,602 patent/US7402591B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0015580A (pt) | Composições analgésicas contendo buprenorfina | |
BR0212019A (pt) | Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem | |
ES8505519A1 (es) | Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos. | |
IL115871A0 (en) | A pharmaceutical composition containing a melt-extruded blend of components and a method for the preparation thereof | |
PT1041987E (pt) | Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona | |
BR9814018A (pt) | Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer | |
RO116342B1 (ro) | Compoziţie farmaceutică lichidă, orală | |
JP2003514013A5 (pt) | ||
BR0202375A (pt) | Composições farmacêutica compreendendo drogas e polìmeros de aumento da concentração | |
MY132705A (en) | Novel compounds with analgesic effect | |
WO2009152189A8 (en) | Low dose topiramate/phentermine compostion and methods of use thereof | |
BR0316948A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
YU49026B (sh) | UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE | |
WO2002058620A3 (es) | Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular | |
MX2009009132A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. | |
BR0215148A (pt) | Composições farmacêuticas de agonista parcial 5ht4 | |
BRPI0413693A (pt) | composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero | |
TR200002078T2 (tr) | Sentetik polisakkaridler, hazırlanmaları için proses ve bunları içeren farmasötik kompozisyonlar. | |
MX2009009134A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno. | |
BR9810337A (pt) | Utilização de um antagonista especìfico dos receptores 5ht2 para a preparação de medicamentos úteis no tratamento da sìndrome de apnéia do sono | |
BR0207866A (pt) | Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna | |
NZ326345A (en) | Composition containing diosgenin | |
BR0008057A (pt) | Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada | |
HU9203022D0 (en) | Pharmaceutical preparatives with upriflavone content methods for production and medical utilization of said compounds | |
ATE289506T1 (de) | Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |